Compare · ARGX vs FDMT
ARGX vs FDMT
Side-by-side comparison of argenx SE (ARGX) and 4D Molecular Therapeutics Inc. (FDMT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and FDMT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.52B, about 73.9x FDMT ($711.0M).
- ARGX has been more active in the news (6 items in the past 4 weeks vs 5 for FDMT).
- ARGX has more recent analyst coverage (25 ratings vs 20 for FDMT).
- Company
- argenx SE
- 4D Molecular Therapeutics Inc.
- Price
- -
- -
- Market cap
- $52.52B
- $711.0M
- 1M return
- -
- -17.35%
- 1Y return
- -
- +7.90%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2020
- News (4w)
- 6
- 5
- Recent ratings
- 25
- 20
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
4D Molecular Therapeutics Inc.
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest FDMT
- 4DMT Announces New Employment Inducement Grants
- SEC Form 4 filed by 4D Molecular Therapeutics Inc.
- 4DMT to Host Investor Day on October 21, 2026
- SEC Form 8-K filed by 4D Molecular Therapeutics Inc.
- 4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
- Chief Legal Officer Bizily Scott exercised 1,635 shares at a strike of $4.14 and sold $22,318 worth of shares (1,635 units at $13.65) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Kirn David sold $811,004 worth of shares (58,333 units at $13.90) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 767,486 units (SEC Form 4)
- 4D Molecular Therapeutics upgraded by Cantor Fitzgerald with a new price target
- 4DMT Announces New Employment Inducement Grants
- Chief Legal Officer Bizily Scott exercised 584 shares at a strike of $6.49 and sold $8,176 worth of shares (584 units at $14.00) as part of a pre-agreed trading plan (SEC Form 4)